80
Participants
Start Date
January 23, 2026
Primary Completion Date
May 14, 2029
Study Completion Date
May 23, 2029
Nerandomilast
Nerandomilast
Placebo
Placebo
Hospital Italiano de Buenos Aires, CABA
Centro de Investigación Clinica Belgrano, CABA
Consultorios Médicos del Buen Ayre, Capital Federal
UZ Leuven, Leuven
Weill Cornell Medicine-New York-60569, New York
University of Pennsylvania, Philadelphia
IRCCS MultiMedica, Milan
Hospital La Princesa, Madrid
Medical University of South Carolina, Charleston
Medizinische Hochschule Hannover, Hanover
HOP Larrey, Toulouse
Lungenfachklinik Immenhausen, Immenhausen
Clinical Research Specialists LLC, Kissimmee
HOP Pontchaillou, Rennes
Azienda Ospedaliera Universitaria di Padova, Padua
Hospital Virgen del Rocío, Seville
Krankenhaus Bethanien gGmbH, Solingen
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen
University of Michigan Health System, Ann Arbor
Hospital de Galdakao, Galdakao
University of Minnesota, Minneapolis
INS Coeur Poumon, Lille
University of Kansas Medical Center, Kansas City
HOP Louis Pradel, Bron
HOP Bichat, Paris
Baylor College of Medicine, Houston
University of California Los Angeles, Los Angeles
Brigham and Women's Hospital, Boston
Centro de Investigaciones Metabolicas (CINME)-C.A.B.A-61553, C.a.b.a
CEDIC - Centro de Investigacion Clinica, CABA
Fachkrankenhaus Coswig GmbH, Coswig
Tosei General Hospital, Aichi, Seto
Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Yokohama
National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Sakai
Hamamatsu University Hospital, Shizuoka, Hamamatsu
National Center for Global Health and Medicine, Tokyo, Shinjuku-ku
St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein
Erasmus Medisch Centrum, Rotterdam
Severance Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital de Bellvitge, L'Hospitalet Del Llobregat
Royal Devon and Exeter Hospital, Wonford, Exeter
Royal Brompton Hospital, London
Lead Sponsor
Boehringer Ingelheim
INDUSTRY